Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | KCNQ3 | O43525 | 14/20 | 0.63 |
| ▸ | KCNQ2 | O43526 | 14/20 | 0.63 |
| ▸ | KCNE1 | P15382 | 9/20 | 0.63 |
| ▸ | KCNQ1 | P51787 | 9/20 | 0.63 |
| ▸ | BACE1 | P56817 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215207 | 0.87 | KCNQ3 (0.81) | SMN1; SMN2RAB9AKCNQ3KCNQ2KCNE1 | |
| SCHEMBL2302302 | 0.83 | RAB9A (0.72) | SMN1; SMN2RAB9AKCNQ3KCNQ2KCNE1 | |
| SCHEMBL3596711 | 0.82 | RAB9A (0.62) | SMN1; SMN2RAB9AKDM4ENPC1MEN1 | |
| SCHEMBL2302037 | 0.82 | KCNQ3 (0.67) | SMN1; SMN2RAB9AKCNQ3KCNQ2KCNE1 | |
| SCHEMBL2302748 | 0.82 | RAB9A (0.74) | SMN1; SMN2RAB9AKCNQ3KCNQ2KCNE1 | |
| SCHEMBL13947158 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2RAB9AKDM4ENPC1MEN1 | |
| SCHEMBL13989051 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2RAB9AALDH1A1LMNAKDM4E | |
| SCHEMBL1020185 | 0.81 | MAPK1 (0.59) | SMN1; SMN2RAB9AALDH1A1LMNAKDM4E | |
| SCHEMBL1845700 | 0.81 | RAB9A (0.58) | SMN1; SMN2RAB9AALDH1A1LMNAKDM4E | |
| SCHEMBL1020999 | 0.81 | P4HTM (0.59) | SMN1; SMN2RAB9AALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010143803-A2 | NEW NICOTINAMIDE DERIVATIVES WITH ANTI-ANDROGEN EFFECTS, PROCESSES OF PREPARING, AND ANTIANDROGENS COMPRISING THE SAME | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143803-A2 | NEW NICOTINAMIDE DERIVATIVES WITH ANTI-ANDROGEN EFFECTS, PROCESSES OF PREPARING, AND ANTIANDROGENS COMPRISING THE SAME | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010143803-A2 | NEW NICOTINAMIDE DERIVATIVES WITH ANTI-ANDROGEN EFFECTS, PROCESSES OF PREPARING, AND ANTIANDROGENS COMPRISING THE SAME | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2010-12-16 | — | — | WO | disclosed |
| US-20040235846-A1 | Administering substituted nicotinamides and nicotinamide analogs for therapy of disorder responsive to the induction of apoptosis in an animal; anti-cancer agents | CYTOVIA, INC. | 2004-11-25 | — | — | US | disclosed |
| US-6794397-B2 | ANTICARCINOGENIC AGENTS | CYTOVIA, INC. | 2004-09-21 | — | — | US | disclosed |
| EP-1257536-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020010185-A1 | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001055115-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010185-A1 | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, BAD, CASP12 | SMN1; SMN2 2117/4885RAB9A 1146/4885KCNQ3 3841/4885 |
| US-20040235846-A1 | Administering substituted nicotinamides and nicotinamide analogs for therapy of disorder responsive to the induction of apoptosis in an animal; anti-cancer agents | NAMPT, BAD, NNT | SMN1; SMN2 988/4885RAB9A 975/4885KCNQ3 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.